Results 31 to 40 of about 7,028 (198)

Comparative short-term efficacy of upadacitinib versus tofacitinib for ulcerative colitis: a 24-week real-world study in Japan [PDF]

Intestinal Research
Background/Aims Tofacitinib and upadacitinib are small-molecule compounds that inhibit the Janus kinase pathway for the treatment of refractory ulcerative colitis.
Akiko Tamura, Hiromichi Shimizu, Toshimitsu Fujii, Ami Kawamoto, Ryo Morikawa, Shuji Hibiya, Kento Takenaka, Masakazu Nagahori, Kazuo Ohtsuka, Ryuichi Okamoto   +9 more
doaj   +1 more source

Upadacitinib in Patients With Difficult-to-Treat Crohn's Disease [PDF]

Upadacitinib has recently been approved for treating Crohn's disease (CD). Here, we report on the effectiveness and safety of upadacitinib in a cohort of patients with difficult-to-treat CD being cared for at clinical centers across ...
Lorenzo Bertani, Paola Balestrieri, Marzo, Manuela, Soriano, Alessandra, Conforti, Francesco Simone, Cristina Bezzio, Principi, Maria Beatrice, Carolina Cavalli, Savarino, Edoardo V, Angela Variola, Bodini, Giorgia, Alessandro Armuzzi, Casini, Valentina, Armuzzi, Alessandro, Michele Campigotto, Variola, Angela, Silvio Danese, Balestrieri, Paola, Manuela Marzo, Aratari, Annalisa, Barberio, Brigida, Annalisa Aratari, Cavalli, Carolina, Calabrese, Emma, Savarino Edoardo, Cappello, Maria, Andrea Michielan, Danese, Silvio, Maria Cappello, Ceccarelli, Linda, Valentina Casini, Bertani, Lorenzo, Alessandra Soriano, Mauro Mastronardi, Federica Furfaro, Franco Scaldaferri, Giorgia Bodini, Giuseppe Biscaglia, Campigotto, Michele, Emma Calabrese, Linda Ceccarelli, Flavio Andrea Caprioli, Mastronardi, Mauro, Furfaro, Federica, Caprioli, Flavio Andrea, Saibeni, Simone, Franchellucci, Gianluca, Biscaglia, Giuseppe, Michielan, Andrea, Simone Saibeni, Bezzio, Cristina, Francesco Simone Conforti, Scaldaferri, Franco, Maria Beatrice Principi, Gianluca Franchellucci, Barberio Brigida   +55 more
core   +6 more sources

Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results [PDF]

, 2022
BACKGROUND: Primary (week 16) results from the ongoing phase 3, double-blind AD Up study (NCT03568318) demonstrate a positive benefit-risk profile for upadacitinib + topical corticosteroid (TCS) in patients with moderate-to-severe atopic dermatitis ...
de Bruin-Weller, Marjolein, Silverberg, Jonathan I, Reich, Kristian, Bieber, Thomas, Soong, Weily, Rosmarin, David, Zeng, Jiewei, Costanzo, Antonio, Chu, Alvina D, Lynde, Charles, Liu, John, Kabashima, Kenji, Ladizinski, Barry, Gamelli, Amy   +13 more
core   +1 more source

Upadacitinib in nail psoriasis: a case report [PDF]

, 2023
The purpose of the article Nail psoriasis is a refractory disease that affects 50–79% skin psoriasis patients and up to 80% of patients with psoriatic arthritis (PsA).
Qing Yang, Hong Liu, Yongxia Liu, Na Wang   +3 more
core   +1 more source

A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysisCapsule Summary

JAAD International, 2022
Background: Systemic atopic dermatitis treatments that have acceptable safety are needed. Objective: To evaluate the safety of the oral Janus kinase inhibitor upadacitinib in combination with topical corticosteroids (TCSs) for the treatment of atopic ...
Norito Katoh, MD, PhD, Yukihiro Ohya, MD, PhD, Hiroyuki Murota, MD, PhD, Masanori Ikeda, MD, PhD, Xiaofei Hu, PhD, Kimitoshi Ikeda, PhD, John Liu, MD, MS, Takuya Sasaki, Alvina D. Chu, MD, Henrique D. Teixeira, PhD, MBA, Hidehisa Saeki, MD, PhD   +10 more
doaj   +1 more source

Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study

RMD Open
Objectives To assess the safety and efficacy of upadacitinib versus adalimumab from SELECT-COMPARE over 5 years.Methods Patients with rheumatoid arthritis and inadequate response to methotrexate were randomised to receive upadacitinib 15 mg once daily ...
Roy Fleischmann, Patrick Durez, Eduardo Mysler, Louis Bessette, Yihan Li, Nasser Khan, Charles G Peterfy, Jerzy Swierkot, Xianwei Bu, Sara K Penn   +9 more
doaj   +1 more source

harmacoeconomic feasibility of using the drug upadacitinib in patients with rheumatoid arthritis in the healthcare system of the Russian Federation

Качественная клиническая практика, 2020
Aim. To assess the pharmacoeconomic feasibility of including the drug upadacitinib in restrictive lists and government funding programs to provide patients with rheumatoid arthritis.Materials and methods.
A. M. Lila, S. K. Zyryanov, I. N. Dyakov
doaj   +1 more source

Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)

Arthritis Research & Therapy, 2021
Background The objective of the study was to evaluate the efficacy and safety of upadacitinib over 84 weeks in Japanese patients with active rheumatoid arthritis (RA) and an inadequate response to conventional synthetic disease-modifying anti-rheumatic ...
Hideto Kameda, Tsutomu Takeuchi, Kunihiro Yamaoka, Motohiro Oribe, Mitsuhiro Kawano, Masayuki Yokoyama, Aileen L. Pangan, Yuko Konishi, Sebastian Meerwein, Yoshiya Tanaka   +9 more
doaj   +1 more source

Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial

Arthritis Research & Therapy
Background To evaluate the efficacy and safety of upadacitinib monotherapy versus methotrexate (MTX) monotherapy over 5 years among MTX-naïve patients with moderately to severely active rheumatoid arthritis (RA) in the long-term extension (LTE) of the ...
Ronald van Vollenhoven, Vibeke Strand, Tsutomu Takeuchi, Nilmo Chávez, Pablo Mannucci Walter, Atul Singhal, Jerzy Swierkot, Nasser Khan, Xianwei Bu, Yihan Li, Sara K. Penn, Heidi S. Camp, Jacob Aelion   +12 more
doaj   +1 more source

From Adult to Adolescent: Alignment in Clinical Trials and Outcomes in Axial Spondyloarthritis

Arthritis Care &Research, Accepted Article.
Spondyloarthritis (SpA) is a group of chronic inflammatory diseases encompassing axial and peripheral forms, with up to 20% of patients developing symptoms before age 16. Despite this substantial pediatric burden, treatment options for juvenile‐onset SpA (JSpA), particularly those with axial disease (axJSpA), remain limited.
Pamela F. Weiss, Judith A. Smith, Robert A. Colbert, Erin Treemarcki, Michael H. Weisman, Walter P. Maksymowych, Hermine I. Brunner, for the CARRA, SPARTAN, and PRCSG Advisory Council   +9 more
wiley   +1 more source